Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COGT Cogent Biosciences	$12.08	$10.75	$3.72 ▼ $12.97	$1.38B	0.36	1.23 million shs	1.06 million shs
CTMX CytomX Therapeutics	$2.04 -0.5%	$2.25	$0.40 ▼ $3.10	$338.07M	2.13	3.92 million shs	1.21 million shs
PAHC Phibro Animal Health	$37.07 -3.6%	$29.34	$16.16 ▼ $38.83	$1.56B	0.8	309,501 shs	644,926 shs
SPRY ARS Pharmaceuticals	$11.62 -9.6%	$16.55	$10.00 ▼ $18.90	$1.27B	0.9	2.00 million shs	7.18 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COGT Cogent Biosciences	0.00%	-0.33%	+4.77%	+124.54%	+16.83%
CTMX CytomX Therapeutics	-0.49%	-3.77%	-12.07%	-19.05%	+75.86%
PAHC Phibro Animal Health	-3.61%	+14.20%	+32.77%	+50.81%	+78.14%
SPRY ARS Pharmaceuticals	-9.64%	-13.93%	-35.01%	-20.84%	-15.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COGT Cogent Biosciences	3.4952 of 5 stars	4.4	3.0	0.0	0.0	2.8	1.7	0.6
CTMX CytomX Therapeutics	4.1652 of 5 stars	3.5	1.0	0.0	4.7	2.8	1.7	1.3
PAHC Phibro Animal Health	4.3254 of 5 stars	1.9	2.0	2.5	1.1	2.1	3.3	3.8
SPRY ARS Pharmaceuticals	2.5599 of 5 stars	3.6	0.0	0.0	0.0	2.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COGT Cogent Biosciences	2.82	Moderate Buy	$19.00	57.28% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.75	181.86% Upside
PAHC Phibro Animal Health	1.83	Reduce	$28.40	-23.39% Downside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	166.78% Upside

Current Analyst Ratings Breakdown

Latest CTMX, COGT, SPRY, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/29/2025	PAHC Phibro Animal Health	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$19.00 ➝ $27.00
8/28/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$34.00
8/25/2025	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $20.00
8/7/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$29.00 ➝ $30.00
8/6/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $21.00
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/18/2025	COGT Cogent Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
7/10/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/8/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $22.00
7/8/2025	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/8/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$0.41 per share	N/A
CTMX CytomX Therapeutics	$138.10M	2.44	$0.36 per share	5.66	$0.73 per share	2.79
PAHC Phibro Animal Health	$1.30B	1.16	$3.15 per share	11.76	$7.05 per share	5.26
SPRY ARS Pharmaceuticals	$89.15M	12.88	$0.01 per share	1,518.60	$1.95 per share	5.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COGT Cogent Biosciences	-$255.86M	-$1.78	N/A	N/A	N/A	N/A	-223.82%	-89.44%	11/11/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.56	3.64	N/A	N/A	34.04%	158.70%	36.04%	11/6/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	31.42	17.65	0.56	3.73%	32.14%	6.89%	11/5/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.49	N/A	N/A	N/A	-42.74%	-21.85%	-15.88%	11/12/2025 (Estimated)

Latest CTMX, COGT, SPRY, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	Q4 2025	PAHC Phibro Animal Health	$0.52	$0.57	+$0.05	$0.42	$362.24 million	$378.70 million
8/13/2025	Q2 2025	SPRY ARS Pharmaceuticals	-$0.41	-$0.46	-$0.05	-$0.46	$12.92 million	$15.72 million
8/5/2025	Q2 2025	COGT Cogent Biosciences	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.29%	N/A	61.54%	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest CTMX, COGT, SPRY, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	PAHC Phibro Animal Health	quarterly	$0.12	1.71%	9/3/2025	9/3/2025	9/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COGT Cogent Biosciences	N/A	4.19	4.19
CTMX CytomX Therapeutics	N/A	4.20	4.20
PAHC Phibro Animal Health	2.46	2.76	1.23
SPRY ARS Pharmaceuticals	0.37	6.17	5.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COGT Cogent Biosciences	N/A
CTMX CytomX Therapeutics	67.77%
PAHC Phibro Animal Health	99.34%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
COGT Cogent Biosciences	7.29%
CTMX CytomX Therapeutics	6.60%
PAHC Phibro Animal Health	50.07%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
CTMX CytomX Therapeutics	170	164.91 million	154.03 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
SPRY ARS Pharmaceuticals	90	98.83 million	65.72 million	Optionable

CTMX, COGT, SPRY, and PAHC Headlines

Recent News About These Companies

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

August 28 at 8:00 AM | globenewswire.com

Vanguard Group Inc. Has $43.88 Million Holdings in ARS Pharmaceuticals, Inc. $SPRY

August 28 at 3:12 AM | marketbeat.com

ARS Pharmaceuticals Inc. (SPRY) Stock Price Today - WSJ

August 24, 2025 | wsj.com

ARS Pharmaceuticals (NASDAQ:SPRY) CFO Sells 12,500 Shares

August 23, 2025 | insidertrades.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 2.3% Following Insider Selling

August 23, 2025 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Insider Sells $173,186.32 in Stock

August 22, 2025 | insidertrades.com

Aberdeen Group plc Takes $12.61 Million Position in ARS Pharmaceuticals, Inc. $SPRY

August 21, 2025 | marketbeat.com

Equities Analysts Issue Forecasts for SPRY FY2025 Earnings

August 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for SPRY FY2025 Earnings

August 19, 2025 | americanbankingnews.com

Leerink Partnrs Issues Negative Forecast for SPRY Earnings

August 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for SPRY Q3 Earnings

August 19, 2025 | marketbeat.com

William Blair Issues Optimistic Forecast for SPRY Earnings

August 19, 2025 | americanbankingnews.com

Leerink Partnrs Issues Pessimistic Outlook for SPRY Earnings

August 19, 2025 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

August 15, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript

August 14, 2025 | msn.com

ARS Pharma Sales Jump 3,040% in Q2

August 14, 2025 | aol.comA

ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For

August 14, 2025 | finance.yahoo.com

ARS Pharmaceuticals Reports Strong Growth for neffy

August 14, 2025 | msn.com

ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2025 | zacks.com

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

August 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, COGT, SPRY, and PAHC Company Descriptions

Cogent Biosciences NASDAQ:COGT

$12.08 0.00 (0.00%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$12.08 0.00 (0.00%)

As of 08/29/2025 06:08 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

CytomX Therapeutics NASDAQ:CTMX

$2.04 -0.01 (-0.49%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.05 +0.01 (+0.54%)

As of 08/29/2025 07:50 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Phibro Animal Health NASDAQ:PAHC

$37.07 -1.39 (-3.61%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$37.06 -0.01 (-0.01%)

As of 08/29/2025 07:17 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

ARS Pharmaceuticals NASDAQ:SPRY

$11.62 -1.24 (-9.64%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$11.65 +0.03 (+0.27%)

As of 08/29/2025 07:49 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time